Key terms
About OCGN
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OCGN news
Apr 09
8:10am ET
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Ocugen (OCGN) and Moderna (MRNA)
Apr 08
6:39am ET
Ocugen: FDA clears IND amendment to initiate Phase 3 clinical trial of OCU400
Apr 05
7:04am ET
Ocugen says DSMB approves medium dose cohort dosing in OCU410 study
Apr 05
3:56am ET
Penny Stock Ocugen (NASDAQ:OCGN) Appears Poised For Bigger and Better Things
Apr 03
6:25am ET
Buy Rating Affirmed for Ocugen on Strong Clinical Progress and Financial Stability
Apr 02
8:24am ET
Ocugen provides business update
Apr 02
7:05am ET
Options Volatility and Implied Earnings Moves Today, April 02, 2024
Apr 01
6:11pm ET
Ocugen announces positive DSMB review of OCU410ST trial
Apr 01
5:22pm ET
Ocugen Inc Regains Nasdaq Compliance with Stock Rebound
Mar 21
4:33pm ET
Ocugen Inc Wins Appeal, Securities Lawsuit Dismissed
Mar 21
12:01pm ET
Ocugen (NASDAQ:OCGN) Blasts Up 16% as Speculation Mounts
Mar 20
5:32pm ET
Ocugen Inc Announces Board Departure and Bylaws Amendment
Mar 18
9:02am ET
Ocugen Inc Bolsters Leadership with New CMO Appointment
Mar 18
6:35am ET
Ocugen names Huma Qamar, MD, MPH as Chief Medical Officer
Mar 13
8:33am ET
Ocugen announces dosing completion of Cohort 1 in OCU410 Phase 1/2 trial
Feb 28
8:14am ET
Ocugen announces availability of Clinical Showcase webcast
Feb 23
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Feb 22
4:09pm ET
Ocugen announces dosing completion in Phase 1/2 GARDian clinical trial
Feb 22
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 22
6:20am ET
Buy Rating Affirmed for Ocugen on Strong Clinical Progress and Positive Financial Outlook
Feb 21
11:32am ET
Ocugen Inc to Present at Clinical Showcase in NYC
Feb 14
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Feb 12
8:46am ET
Ocugen price target raised to $8 from $5 at Noble Capital
Jan 24
6:08am ET
Ocugen price target raised to $7 from $5 at H.C. Wainwright
Today
1:01pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
Today
9:00am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
Yesterday
1:19pm ET
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Yesterday
1:00pm ET
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
Apr 16
10:15pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
Apr 16
5:36pm ET
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
Apr 16
1:13pm ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Apr 15
12:00pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
Apr 14
6:00pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Apr 14
2:18pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ocugen, Inc. - OCGN
Apr 14
7:12am ET
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
Apr 13
8:00pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
Apr 13
5:00pm ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Apr 12
4:14pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Apr 12
2:10pm ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
Apr 12
4:30am ET
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
Apr 08
7:30am ET
OCGN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if You Lost Money on Your Ocugen, Inc. investment
Apr 06
2:18pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ocugen, Inc. - OCGN
OCGN Financials
Key terms
Ad Feedback
OCGN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
OCGN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
